OABI Stock Overview
OmniAb, Inc., a biotechnology company, provides therapeutic antibody discovery technologies in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
My Notes
NewNotes are coming soon
OmniAb, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.34 |
| 52 Week High | US$10.50 |
| 52 Week Low | US$1.91 |
| Beta | 0 |
| 1 Month Change | 34.37% |
| 3 Month Change | 100.93% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -51.45% |
Recent News & Updates
Recent updates
Shareholder Returns
| OABI | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | -0.5% | 2.7% | 2.9% |
| 1Y | n/a | -10.4% | -8.5% |
Return vs Industry: Insufficient data to determine how OABI performed against the US Life Sciences industry.
Return vs Market: Insufficient data to determine how OABI performed against the US Market.
Price Volatility
| OABI volatility | |
|---|---|
| OABI Average Weekly Movement | 16.6% |
| Life Sciences Industry Average Movement | 11.7% |
| Market Average Movement | 6.8% |
| 10% most volatile stocks in US Market | 17.6% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: OABI is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 17% a week.
Volatility Over Time: Insufficient data to determine OABI's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 93 | Matt Foehr | https://www.omniab.com |
OmniAb, Inc., a biotechnology company, provides therapeutic antibody discovery technologies in the United States. The company’s discovery platform provides industry partners access to the diverse antibody repertoires and screening technologies to enable discovery of next-generation therapeutics. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates.
OmniAb, Inc. Fundamentals Summary
| OABI fundamental statistics | |
|---|---|
| Market Cap | US$498.32m |
| Earnings (TTM) | -US$32.23m |
| Revenue (TTM) | US$39.01m |
12.8x
P/S Ratio-15.5x
P/E RatioIs OABI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| OABI income statement (TTM) | |
|---|---|
| Revenue | US$39.01m |
| Cost of Revenue | US$0 |
| Gross Profit | US$39.01m |
| Other Expenses | US$71.24m |
| Earnings | -US$32.23m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.28 |
| Gross Margin | 100.00% |
| Net Profit Margin | -82.61% |
| Debt/Equity Ratio | 0% |
How did OABI perform over the long term?
See historical performance and comparison